ArticleBMC pregnancy and childbirth2026
Serum xenopsin-related peptide-1 levels in pregnant women with hyperemesis gravidarum; a cross-sectional study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate serum xenopsin-related peptide (XRP) -1 levels in women with hyperemesis gravidarum (HEG) from the onset of pregnancy until the end of week 14. MATERIALS AND
methodsThis cross-sectional study was conducted at the Antalya Training and Research Hospital Obstetrics Clinic, Türkiye, between July and December 2024. Forty-five pregnant diagnosed with HEG and 45 healthy pregnant were included. Venous blood samples for the XRP-1 test were collected from pregnant women and the collected serum samples were stored at -80 degrees until the day of analysis.
resultsSignificant differences were observed between the HEG and healthy groups in terms of serum thyroid-stimulating hormone (1.86 ± 0.54 vs. 1.38 ± 0.67, respectively, p = 0.027), potassium (3.84 ± 0.45 vs. 3.58 ± 0.60, p = 0.010), and XRP-1 (4.33 ± 1.66 vs. 2.38 ± 1.32, p < 0.001) values. At receiver operating characteristic analysis, the area under the curve (AUC: 0.824) was statistically significant for serum XRP-1 (p < 0.001), with a cut-off value of ≥ 2.42 [95% confidence interval 0.731-0.917, 82.2% sensitivity, and 80.0% specificity]. The positive predictive value of serum XRP-1 was 80.0% and the negative predictive value was 81.0%. CONCLUSION(S): This study suggests that serum XRP-1 levels are elevated in HEG. Further studies are now needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.